Clinical Characteristics of Patients With Prolonged Disease-Free Survival After Primary Treatment in Advanced Ovarian Cancer: A Brief Report. Issue 3 (1st April 2011)

• Record Type: Journal Article
• Authors: Milam, Michael R.; Harrell, Robyn; Bassett, Roland; Parker, Lynn P.; Metzinger, Daniel S.; Ramirez, Pedro T.
• Is Part Of: International journal of gynecological cancer. Volume 21:Issue 3(2011)
• Page Start: 475
• Page End: 477
• Publication Date: 2011-04-01
• Subjects: Neoadjuvant chemotherapy -- Ovarian cancer -- Survival; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0b013e31820bf251
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Optimal cytoreduction and response to chemotherapy have been associated with prolonged disease-free survival (DFS), but there are limited data regarding the clinical characteristics of those patients with optimal 5-year DFS (5YrDFS) outcomes. Methods: A case-control study was performed on 32 patients who were progression-free and alive at 5 years with advanced ovarian cancer 5YrDFS from 1993 to 2005 for this institutional review board-approved study. Matching controls were identified from the subset of patients who died or experienced disease progression before 5 years. Results: One hundred sixty patients were evaluated. There was no statistical difference between cases and controls in regard to neoadjuvant chemotherapy, grade, race, preoperative cancer antigen-125 level, optimal cytoreduction, operating room time, length of hospital stay, or total chemotherapy cycles in regard to 5YrDFS. If a patient achieved complete response after primary treatment, the likelihood of progression-free survival 5 years or longer is 7 times more likely, (odds ratio = 7.2 [95% confidence interval = 2.3-22.4]; P = 0.0006). Conclusion: In this matched case-control analysis, complete response after primary treatment was the only significant factor associated with 5YrDFS. Further study is needed in patient and tumor characteristics to identify those patients who may have poor or favorable outcomes before treatment completion.